Hepatitis C virus genotypes in hemodialysis patients in Angola

Borges, Luis Filipe da Costa Marques; Zalis, Mariano Gustavo; Santoro‐Lopes, Guilherme; Varella, Rafael Brandão

doi:10.1002/jmv.25354

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, access to diagnosis and treatment of HCV infection is limited in low-income countries, and there is currently no effective vaccine against HCV. On World Hepatitis Day 2021, the theme “Hepatitis can’t wait” underlined the importance of the urgency of eradicating hepatitis in order to meet the 2030 elimination targets [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

The world prevalence, associated risk factors and mortality of hepatitis C virus infection in hemodialysis patients: a meta-analysis

et al. 2022

View full text Add to dashboard Cite

Background The worldwide burden of HCV infection among hemodialysis patients has not been systematically examined. Methods A systematic literature search was conducted in MEDLINE and Scopus to determine the worldwide prevalence of HCV infection, risk factors, and clinical outcomes among hemodialysis patients. Random-effect models and meta-regressions were used to generate pooled estimates and assess heterogeneity. Results Four hundred and seven studies with 1,302,167 participants were analyzed. The pooled prevalence of HCV infection was 21%. The highest prevalence was observed in Africa (28%) and low-income countries (48.5%). A significant prevalence decline was observed following the publication year and was also inversely related to GDP and total population of each country. Factors associated with HCV positivity included younger age, longer dialysis duration, more blood transfusions, and dialyzer reuse. The pooled unadjusted hazard ratio for all-cause mortality was 1.12 (95% CI 1.03–1.22), and the adjusted hazard ratio was 1.21 (95% CI 1.12–1.30) in HCV-infected compared to non-HCV infected patients. Conclusions HCV infection among hemodialysis patients is a worldwide shared burden and is associated with a higher risk of death. Avoiding unnecessary blood transfusion and dialyzer reuse should be encouraged to prevent HCV transmission in hemodialysis units. Supplementary Information The online version contains supplementary material available at 10.1007/s40620-022-01483-x.

show abstract

Section: Introductionmentioning

confidence: 99%

The world prevalence, associated risk factors and mortality of hepatitis C virus infection in hemodialysis patients: a meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

The hidden risk of health-care-associated hepatitis C virus infection: Scenarios, past, present, and future

Naveen

Naidu

Ramesh

et al. 2021

Recent Developments in Applied Microbiology and Biochemistry

View full text Add to dashboard Cite

The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis

Adane

Getawa

2021

PLoS ONE

View full text Add to dashboard Cite

Background Due to its invasive procedure patients on hemodialysis (HD) are at high risk of infections. Infections acquired in dialysis units can prolong hospitalization date and/or prolong illness in patients, and increase treatment cost. There are no adequate data on the prevalence of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections in HD patients. Therefore, this study aimed to estimate the pooled prevalence and associated factors of HBV and HCV infections among HD patients in Africa. Method The databases PubMed, Medline, EMBASE, Cochrane library, web of science, African Journals Online, Science Direct, and Google Scholar were searched to identify relevant studies. The review was performed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data were extracted independently by two authors and analyzed using STATA 11. A random-effect model was fitted to estimate the pooled prevalence with their 95% confidence interval. To detect publication bias funnel plots analysis and Egger weighted regression tests were done. Results The overall pooled prevalence of HBV and HCV infection among HD patients in Africa was 9.88% (95% CI: 7.20–12.56) I2 = 97.9% and 23.04% (95% CI: 18.51–2757) I2 = 99.6%, respectively. In addition, the pooled prevalence of HBV and HCV co-infection was 7.18% (95% CI: 3.15–11.20) I2 = 99.6%. Duration of dialysis was found to be the contributing factor for the occurrence of HBV and HCV among HD patients (OR = 1.44; 95% CI: 1.04, 2.01). Conclusion This study showed that there is high prevalence of HBV and HCV infections in HD patients in Africa. Therefore, strict adherence to precautions of infection control measures, isolation of seropositive patients, improvement in infrastructures, adequate screening of HBV and HCV for the donated blood, and decentralized HD services is needed to minimize the risk of HBV and HCV infections in HD facilities.

show abstract

Hepatitis C virus genotypes in hemodialysis patients in Angola

Cited by 3 publications

References 17 publications

The world prevalence, associated risk factors and mortality of hepatitis C virus infection in hemodialysis patients: a meta-analysis

The world prevalence, associated risk factors and mortality of hepatitis C virus infection in hemodialysis patients: a meta-analysis

The hidden risk of health-care-associated hepatitis C virus infection: Scenarios, past, present, and future

The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis

Contact Info

Product

Resources

About